Allurion Technologies, a company focused on obesity treatment, announced a registered direct offering of 1,240,000 shares of common stock...

Merck and Eisai announced results from the Phase 3 LEAP-015 trial, which examined the efficacy of Keytruda plus Lenvima...

Exelixis announced positive results from a subgroup analysis of the phase 3 CABINET study, showing cabozantinib improved progression-free survival...

Median Technologies secured a non-binding term sheet with the European Investment Bank (EIB) for a loan of up to...

Elevar Therapeutics announced positive results from a post-hoc analysis of the CARES-310 study, showing that camrelizumab plus rivoceranib provides...

Axiom Brain Health, in partnership with the Global Alzheimer’s Platform Foundation (GAP), launched its newly renovated research facility in...

Firefly Neuroscience highlighted two studies demonstrating the potential of its FDA-cleared Brain Network Analytics (BNA™) platform in drug development...

A Phase 3 CheckMate-8HW trial analysis revealed that Opdivo plus Yervoy significantly improved progression-free survival (PFS) compared to Opdivo...

Exelixis announced results from the STELLAR-001 trial, a Phase 1b/2 study evaluating zanzalintinib, alone or combined with atezolizumab, in...

In this conversation with Christine Guo, Chief Scientific Officer at ActiGraph, we explored the impact of Actigraph’s acquisition of...